

David Rasnick

I received my PhD in chemistry from Georgia Tech in 1978. I have BS degrees in biology and chemistry.

I have 25 years experience with proteases and protease inhibitors, and worked 20 years in pharmaceutical industry developing protease inhibitors for tissue destroying diseases: cancer, emphysema, arthritis, parasitic diseases.

I began my professional career at Abbott Laboratories in 1978 where I helped establish the chemistry group in the Diagnostics Division. I left Abbott in 1980 to become one of the founders of Enzyme Systems Products and Prototek. In 1993 I was a senior scientist for Khepri Pharmaceuticals, which was acquired by Arris Pharmaceuticals. I left Arris in 1996 and went across the Bay, where I worked closely with Professor Peter Duesberg at University of California at Berkeley for 10 years on the aneuploidy (or chromosomal imbalance) theory of cancer. Based on that research, I founded Boveran, Inc. in 1999, and Chromosome Diagnostics, LLC, in 2008.

As an extension of my theoretical work on the aneuploidy theory of cancer, I invented DATE analysis, which stands for Differentiation, Adaptation, Transformation, Evolution. DATE analysis is a general theory of biological change, bridging the gulf between genotype and phenotype. DATE differs from metabolic control analysis (on which it is based) in that its essential task lies in the comparison of related phenotypes rather than in the precise definition or description of each.

I am former President of Rethinking AIDS: the group for the scientific reappraisal of the HIV hypothesis and former President of the International Coalition for Medical Justice. From 2000-2008 I was a member of the Presidential AIDS Advisory Panel of South Africa.